Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma

Author： Quinn David I.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.48, Iss.3, 2009-01, pp. : 199-209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma

By Hellmann Andrzej  

Clinical Pharmacokinetics, Vol. 50, Iss. 12, 2011-12 ,pp. : 781-791

Adis International

Access to resources Recommend Favorite

The Effect of Aging on the Relationship between the Cytochrome P450 2C19 Genotype and Omeprazole Pharmacokinetics

By Ishizawa Yukio   Yasui-Furukori Norio  

Clinical Pharmacokinetics, Vol. 44, Iss. 11, 2005-01 ,pp. : 1179-1189

Adis International

Access to resources Recommend Favorite

Plerixafor: In Patients with Non-Hodgkin's Lymphoma or Multiple Myeloma

By Wagstaff Antona J.  

Drugs, Vol. 69, Iss. 3, 2009-02 ,pp. : 319-326

Adis International

Access to resources Recommend Favorite

Cytochrome P450 2C19 (CYP2C19) genotype appears to affect the efficacy of omeprazole

By  

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

Blackwell Publishing

Access to resources Recommend Favorite